ArticleScientific reports2025
Serum NSE and EEG sleep figures for prognostication of short-term outcomes in adults with severe COVID-19 pneumonia: a prospective single-center study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is associated with encephalopathy, but its diagnosis and prognostic value has yet to be fully characterized. We aimed to examine key neurobiomarkers of encephalopathy in patients with severe COVID-19 pneumonia, specifically serum neuron-specific enolase (NSE), serum S100-beta protein (S100B), and early electroencephalographic (EEG) abnormalities, and their association with short-term outcomes. We conducted a prospective, single-center cohort study including consecutive adult patients with COVID-19 admitted to the intensive care unit (ICU) for acute respiratory failure. NSE and S100B levels were measured on days 1, 2, and 3 post-admission, and standard EEG was performed as part of routine neuromonitoring. The primary outcome was mortality at 90 days. Among 134 included patients, 47 (35.1%) died within 90 days. NSE concentrations on days 1, 2, and 3 were significantly associated with mortality and intubation, whereas S100B concentrations were not. In multivariable analyses, maximal NSE concentration between day 1 and day 3 (adjusted odds ratio (aOR) 1.15, 95% CI 1.06–1.24), absence of EEG sleep figures (aOR 14.28, 95% CI 2.38–76.92), age (aOR per 1-point 1.10, 95% CI 1.04–1.17), and SOFA score (aOR per 1-point 1.28, 95% CI 1.01–1.62) were independently associated with mortality. NSE predicted mortality with an area under the Receiver Operating Characteristic curve of 0.72 (95% CI 0.61–0.82). An NSE threshold > 34microg/L predicted mortality with a specificity of 95% (95% CI 87–99%) and a sensitivity of 24% (95% CI 13–40%). Among patients with severe COVID-19 pneumonia, elevated serum NSE levels and absence of EEG sleep features, suggesting subclinical encephalopathy, were independently associated with increased mortality. These findings support the use of serum NSE and EEG as early prognostic biomarkers in critically ill patients without primary brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.